Content about Abbott Laboratories

January 8, 2013

Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

NEW YORK — Abbott Labs has spun off its specialty drug division into a new company called AbbVie, which the new company's leaders heralded Wednesday by ringing the first opening bell of 2013 at the New York Stock Exchange.

January 4, 2013

According to a Bloomberg report, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion.

NEW YORK — According to a Bloomberg report published Friday morning, Abbott Laboratories, Johnson & Johnson and Sanofi are all potential suitors for Bausch & Lomb's eye care business in a deal that could be valued as high as $10 billion. 

B&L is being shopped by private equity firm Warburg Pincus, which is working with Goldman Sachs Group, Bloomberg reported, and both Abbott and Sanofi have contracted financial advisors as well. 

Other companies who have been invited to bid include Merck and Pfizer. 

November 2, 2012

Abbott and its foundation, the Abbott Fund, on Friday announced that $1 million in funding and product donations will be made to support relief efforts in response to Hurricane Sandy.

ABBOTT PARK, Ill. — Abbott and its foundation, the Abbott Fund, on Friday announced that $1 million in funding and product donations will be made to support relief efforts in response to Hurricane Sandy. The Abbott Fund grants will be provided to long-standing relief organization partners, including the American Red Cross, AmeriCares, Direct Relief International and World Vets. 

Abbott product donations have been made to Direct Relief International and Feeding America.

September 21, 2012

According to "Nutritional Supplements in the U.S.," a report released earlier this week from Packaged Facts, supplement sales rose 7% to $11.5 billion in 2012, and are forecasted to reach $15.5 billion by 2017.

ROCKVILLE, Md. — According to "Nutritional Supplements in the U.S.," a report released earlier this week from Packaged Facts, supplement sales rose 7% to $11.5 billion in 2012, and are forecasted to reach $15.5 billion by 2017.

The report cited a number of factors, including a recovering economy that should have more consumers picking up on supplementing again, the aging baby boomer and a growing Hispanic population that is heavily indexed as supplement users. 

August 29, 2012

A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

WASHINGTON — A panel of outside advisers to the Food and Drug Administration has backed wider use for Abbott Labs’ rheumatoid arthritis drug, Humira, for treating a type of inflammatory bowel disease.

According to published reports, the panel voted 15-2 that the benefits of Humira outweighed the risks in treating ulcerative colitis. However, the panel asked Abbott to conduct more studies upon Humira's approval.

April 11, 2012

Move over, Lipitor: There's a new top drug on the market, according to published reports.

NEW YORK — Move over, Lipitor: There's a new top drug on the market, according to published reports.

March 19, 2012

Watson Pharmaceuticals is challenging the patent protection on a drug made by Abbott for treating cholesterol, the company said.

PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging the patent protection on a drug made by Abbott for treating cholesterol, the company said.

Watson, through a subsidiary, filed with the Food and Drug Administration for approval of niacin extended-release tablets in the 500-mg and 1,000-mg strengths. The drug is a generic version of Abbott's Niaspan.

December 2, 2011

Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

PITTSBURGH — Under the President's Emergency Plan for AIDS Relief, the Food and Drug Administration has given tentative approval to a generic HIV and AIDS drug made by Mylan, the company said.

The drug maker's Mylan Labs subsidiary received tentative approval for atazanavir sulfate and ritonavir tablets in the 300-mg/100-mg strength. The FDA's tentative approval of the drug under PEPFAR means it will be eligible for purchase in certain developing countries.

November 7, 2011

A large number of patients with a serious form of arthritis experienced improvement in their condition after taking a drug made by Abbott Labs for three months, according to results of a late-stage clinical trial announced Monday.

ABBOTT PARK, Ill. — A large number of patients with a serious form of arthritis experienced improvement in their condition after taking a drug made by Abbott Labs for three months, according to results of a late-stage clinical trial announced Monday.

October 3, 2011

The National Advertising Division of the Council of Better Business Bureaus last week determined Abbott Nutrition could support certain advertising claims made for Similac Advance and Similac Sensitive infant formula. However, NAD recommended that Abbott modify or discontinue certain other claims.

NEW YORK — The National Advertising Division of the Council of Better Business Bureaus last week determined Abbott Nutrition could support certain advertising claims made for Similac Advance and Similac Sensitive infant formula. However, NAD recommended that Abbott modify or discontinue certain other claims.

NAD determined that Abbott had a reasonable basis for its “No. 1 brand-fed in hospitals” claim.

November 29, 2010

Generic drug maker Impax Labs is challenging the patent covering a drug used to treat high cholesterol, the company said Friday.

HAYWARD, Calif. — Generic drug maker Impax Labs is challenging the patent covering a drug used to treat high cholesterol, the company said Friday.

Impax said it had filed an approval application with the Food and Drug Administration for niacin and simvastatin extended-release tablets in the 1,000 mg/20 mg strength. The drug is a generic version of Abbott Labs’ Simcor.

September 21, 2010

Abbott on Wednesday initiated a proactive, voluntary recall of certain Similac powder infant formulas in...

ABBOTT PARK, Ill. Abbott on Wednesday initiated a proactive, voluntary recall of certain Similac powder infant formulas in the United States, Puerto Rico, Guam and some countries in the Caribbean following an internal quality review, which detected the remote possibility of the presence of a small common beetle in the product, produced in one production area in a single manufacturing facility.

May 20, 2010

Although Mead Johnson has said it voluntarily will modify or discontinue certain advertising claims for...

May 4, 2010

A subsidiary of Watson Pharmaceuticals is challenging the patent to a drug for high cholesterol,...

March 8, 2010

Abbott Nutrition on Monday launched a new print ad campaign supporting its EAS brand, positioning...